Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can aspirin or diabetes drugs tame fatty liver? new study reveals results

NCT ID NCT07338331

Disease control Sponsor: Galala University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study looked at whether aspirin or a diabetes drug called an SGLT2 inhibitor (like dapagliflozin) can improve liver health in people with type 2 diabetes and non-alcoholic fatty liver disease. Researchers measured liver enzymes, cholesterol, and liver stiffness (using FibroScan) in 80 adults over 6 months. The goal was to see which treatment better controls liver damage and metabolic symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Apr 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: if one or more the following are present: * Diabetes mellitus, unless receiving only Dapagliflozin for treatment. * Adult individuals (18-65 years) with a clinical diagnosis of NAFLD based on liver ultrasound * No history of alcohol consumption or consumption within 3 months. * Absence of other liver diseases. * No significant renal or gastrointestinal issues that could interfere with treatment. Exclusion Criteria:Patients were excluded from our study if one or more the -following are present: * Pregnancy or breastfeeding. * Active chronic viral hepatitis or autoimmune liver disease. * History of gastrointestinal bleeding or other contraindications for Aspirin. * Severe renal insufficiency. * Alcohol intake

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete type 2 Non alcoholic fatty liver

Contacts and locations

Locations

  • Faculty of Pharmacy

    Banī Suwayf, Beni Suweif Governorate, 0000, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.